{
    "nctId": "NCT02101554",
    "officialTitle": "AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PF-06412528 IN CHILDREN 7-17 YEARS FOR THE TREATMENT OF MODERATE-TO-SEVERE PAIN",
    "inclusionCriteria": "* Children 7-17 with moderate to severe pain requiring around the clock treatment with an opioid analgesic.\n* Be an experienced opioid user, defined as any subject treated with opioid therapy, equivalent or equal to \\>20 mg per day of morphine, for a period of 3 consecutive days immediately prior to first day of dosing.\n* Must have minimum age of 7 Years\n* Must have maximum age of 17 Years",
    "exclusionCriteria": "* Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation and behavior in past year.\n* Hypersensitivity to morphine, naltrexone.\n* A life expectancy (assessed by investigator) of less than 6 months or is no longer capable of taking medication orally.\n* Undergone surgery within 3 days prior to the first day of dosing."
}